Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
SchaeffersResearch.com48m
Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm ...
Mobile App Hitmaker Dream Games Discussing $2.5 Billion Raise
Dream Games, a Turkish developer of popular mobile games including Royal Match, is in talks with investors to raise around $2.5 billion in fresh debt and equity in a round that would almost double the ...
Alaska Dispatch News12m
Federal Reserve likely to hold rates steady, despite Trump call for cuts, as it awaits tariff and immigration developments
Outside of a U.S. President bending norms, the Fed also faces challenges in achieving its economic objectives. Inflation ...